Report of Foreign Issuer (6-k)
March 27 2017 - 5:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report
of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
March 27, 2017
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CK
Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including ZIP Code, and Telephone Number, Including Area Code, of Registrants Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On March 27, 2017, ProQR Therapeutics N.V. issued a press releases titled, ProQR
Appoints David M. Rodman, MD as Chief Development Strategy Officer. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained
herein into the Companys registration statement on Form F-3 (File No. 333-207245).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PROQR THERAPEUTICS N.V.
|
|
|
|
|
Date: March 27, 2017
|
|
|
|
By:
|
|
/s/ Smital Shah
|
|
|
|
|
|
|
Smital Shah
Chief Financial
Officer
|
|
|
|
|
|
|
|
INDEX TO EXHIBITS
|
|
|
Number
|
|
Description
|
|
|
99.1
|
|
Press Release of ProQR Therapeutics N.V. dated March 27, 2017, titled ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer.
|
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Sep 2023 to Sep 2024